Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Associated Therapies: -

Clinical Trials

Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Nebivolol
Drug: Hydrochlorothiazide

First Posted Date: 2009-10-22

Last Posted Date: 2011-05-05

Lead Sponsor: InVasc Therapeutics, Inc.

Target Recruit Count: 40

Registration Number: NCT00999752

Locations: 🇺🇸
Atlanta Vascular Research Foundation, Tucker, Georgia, United States

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

Phase 4

Withdrawn

Conditions: Hypertension
Diabetes Type 2

Interventions: Drug: Aliskiren
Drug: Hydrochlorothiazide

First Posted Date: 2009-10-14

Last Posted Date: 2017-10-02

Lead Sponsor: William Beaumont Hospitals

Registration Number: NCT00994253

Locations: 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States

A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM

Phase 4

Completed

Conditions: Hypertension
Type 2 Diabetes Mellitus

Interventions: Drug: Hydrochlorothiazide
Drug: Indapamide

First Posted Date: 2009-09-18

Last Posted Date: 2011-06-15

Lead Sponsor: LaborMed Pharma S.A.

Target Recruit Count: 56

Registration Number: NCT00980187

Locations: 🇷🇴
Cardiology, University and Emergency Hospital, Bucharest, Romania

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Hydrochlorothiazide
Drug: Dapagliflozin
Drug: Placebo

First Posted Date: 2009-09-14

Last Posted Date: 2017-03-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 154

Registration Number: NCT00976495

Locations: 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸
Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, United States
🇳🇱
Local Institution, Groningen, Netherlands

and more 7 locations

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Conditions: Diabetes Mellitus
Arterial Hypertension

Interventions: Drug: Metformin
Drug: Glybenclamide
Drug: NPH insulin
Drug: Hydrochlorothiazide
Drug: Propranolol
Drug: Captopril
Drug: Amlodipine

First Posted Date: 2009-07-09

Last Posted Date: 2011-10-26

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 124

Registration Number: NCT00935805

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Hydrochlorothiazide

First Posted Date: 2009-06-23

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 894

Registration Number: NCT00926289

Locations: 🇺🇸
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
🇨🇳
502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇨🇳
502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China

and more 103 locations